orforglipron vs tirzepatide Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial Orforglipron vs tirzepatide: the complete

At 9mg weekly: Nausea: 38.1% Diarrhea: 34.7% Constipation: 21.8% Vomiting: approximately 15-20% At 12mg weekly: Nausea: 43.2% Diarrhea: 33.1% Constipation: 25.0% Vomiting: approximately 18-22% These numbers look concerning, but context matters

Apr 2, 2026 Americans pay more for GLP-1 medications than almost anyone else on earth

Visit our Endocrinology Department at Continental Hospitals, Hyderabad, for expert evaluation, advanced care, and personalized treatment from our specialists

Before you apply for a new line of credit just to afford a weekly injection, it's worth comparing financed retail pricing to flat cash-pay protocol pricing because in many cases, the cheapest path isn't the one with the longest payment plan

These results inform dosing decisions because they show that higher doses generally produce more weight loss, but the incremental benefit between 10 mg and 15 mg is smaller than between 5 mg and 10 mg